Bio-Thera(SH:688177) Xin Lang Cai Jing·2026-01-09 05:59Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a significant increase in price and trading activity, indicating positive market sentiment despite some fluctuations in recent months [1][2]. - As of January 9, Baiotai's stock price rose by 2.03% to 25.08 CNY per share, with a total market capitalization of 10.385 billion CNY [1]. - The company has experienced an 8.38% increase in stock price year-to-date, with a 5.82% increase over the past 20 days, although it has seen a 7.11% decline over the last 60 days [2]. Group 2 - Baiotai's main business involves the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2]. - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, reflecting a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a 38.72% increase in losses compared to the previous year [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and cancer treatment [2].